Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Oxford Biodynamics PLC

Healthcare GB OBD

0.19GBX
0.00(0%)

Last update at 2026-06-05T15:28:00Z

Day Range

0.180.20
LowHigh

52 Week Range

0.180.78
LowHigh

Fundamentals

  • Previous Close 0.19
  • Market Cap8.15M
  • Volume7577127
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.26600M
  • Revenue TTM1.09M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.52M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -11.42200M -11.95600M -11.41100M -7.56700M -7.62900M
Minority interest 0.00000M 0.00000M 0.00000M 0.00000M -
Net income -11.15300M -11.56700M -10.82600M -6.71000M -6.68200M
Selling general administrative 4.01M 4.48M 3.41M 2.45M 1.85M
Selling and marketing expenses - - 0.03M - -
Gross profit -6.14900M 0.29M 0.27M 0.12M -0.55700M
Reconciled depreciation 1.20M 1.47M 1.36M 1.21M 1.09M
Ebit -11.00000M -11.73100M -11.19800M -8.60100M -7.51200M
Ebitda -9.80100M -10.26500M -9.84100M -7.25400M -6.39300M
Depreciation and amortization 1.20M 1.47M 1.36M 1.35M 1.12M
Non operating income net other - - - - -
Operating income -10.66300M -12.89400M -11.02600M -8.60100M -7.51200M
Other operating expenses 11.76M 13.53M 11.51M 8.76M 7.85M
Interest expense 0.42M 0.23M 0.21M 0.20M 0.15M
Tax provision -0.26900M -0.38900M -0.58500M -0.85700M -0.94700M
Interest income 0.06M 0.11M 0.07M 0.13M 0.03M
Net interest income -0.35900M -0.11300M -0.14100M -0.06100M -0.11700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.26900M -0.38900M -0.58500M -0.85700M -0.94700M
Total revenue 1.09M 0.64M 0.51M 0.15M 0.34M
Total operating expenses 4.51M 13.18M 10.43M 8.72M 6.96M
Cost of revenue 7.24M 0.35M 0.24M 0.04M 0.90M
Total other income expense net -0.75900M 0.94M -0.41600M 1.03M -0.11700M
Discontinued operations - - - - -
Net income from continuing ops -11.15300M -11.56700M -10.82600M -6.71000M -6.68200M
Net income applicable to common shares - - - -6.71000M -6.68200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 8.09M 12.11M 16.13M 11.34M 15.38M
Intangible assets 1.11M 1.35M 1.91M 1.60M 1.15M
Earning assets - - - - -
Other current assets - 0.51M 1.64M 1.43M 1.95M
Total liab 6.97M 7.75M 10.07M 8.76M 8.69M
Total stockholder equity 1.12M 4.36M 6.05M 2.59M 6.68M
Deferred long term liab - - - - -
Other current liab 0.72M -0.48200M 1.76M 0.17M 0.29M
Common stock 4.83M 3.12M 2.02M 1.00M 0.93M
Capital stock 4.83M 3.12M 2.02M 1.00M 0.93M
Retained earnings -52.16900M -42.11900M -30.82500M -20.70900M -14.17100M
Other liab - - - 0.45M 0.44M
Good will - - - - -
Other assets - - -0.00000M - -
Cash 1.39M 1.83M 5.25M 0.97M 2.17M
Cash and equivalents - - - - -
Total current liabilities 2.61M 2.56M 4.00M 2.91M 2.29M
Current deferred revenue - - 0.12M - -
Net debt 3.72M 3.91M 1.19M 5.16M 4.41M
Short term debt 1.29M 2.09M 1.64M 0.74M 0.63M
Short long term debt - - - - -
Short long term debt total 5.11M 5.74M 6.44M 6.14M 6.59M
Other stockholder equity 45.38M 40.15M 32.14M 22.29M 19.92M
Property plant equipment - - - 6.98M 7.55M
Total current assets 2.28M 5.05M 7.17M 2.77M 6.68M
Long term investments - - - - -
Net tangible assets - - - 0.99M 5.52M
Short term investments - 1.00M - 0.03M 2.16M
Net receivables 0.69M 1.39M 1.64M 1.43M 1.95M
Long term debt - - - - -
Inventory 0.20M 0.32M 0.27M 0.34M 0.39M
Accounts payable 0.59M 0.95M 0.48M 2.00M 1.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.08M 3.21M 2.71M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 5.80M 7.06M 8.96M 8.58M 8.70M
Capital lease obligations 5.11M 5.74M 6.44M 6.14M 6.59M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments 1.00M -1.48500M -0.62000M 1.25M 2.83M
Change to liabilities - - - 0.47M 0.42M
Total cashflows from investing activities 0.76M -1.48500M -0.69100M 1.25M 2.83M
Net borrowings - - - -0.70300M -0.80400M
Total cash from financing activities 6.52M 8.25M 13.42M 2.56M -0.80400M
Change to operating activities - - - - -
Net income -11.15300M -11.95600M -10.82600M -7.56700M -7.62900M
Change in cash -0.43500M -3.42300M 4.28M -1.20100M -3.94400M
Begin period cash flow 1.83M 5.25M 0.97M 2.17M 6.12M
End period cash flow 1.39M 1.83M 5.25M 0.97M 2.17M
Total cash from operating activities -7.70900M -10.17200M -8.43600M -5.17700M -5.91800M
Issuance of capital stock 7.44M 9.86M 15.39M 3.62M -
Depreciation 1.20M 1.47M 1.36M 1.21M 1.09M
Other cashflows from investing activities 1.00M -1.40500M -0.46600M 0.01M 2.69M
Dividends paid - - - - -
Change to inventory 0.13M -0.04700M 0.06M 0.06M -0.06900M
Change to account receivables 0.96M -0.42700M -0.44800M 0.47M -0.56000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.65600M -1.60600M -1.96700M -1.06100M 2.83M
Change to netincome - - - -0.67900M -0.11100M
Capital expenditures 0.02M 0.59M 0.72M 0.90M 3.09M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.90M -0.64100M -0.67100M 1.00M -0.21300M
Stock based compensation 0.50M 0.51M 0.33M 0.39M 0.25M
Other non cash items 1.35M 0.45M 1.37M -0.21600M 0.08M
Free cash flow -7.72600M -10.76700M -9.01000M -6.07800M -9.00700M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OBD
Oxford Biodynamics PLC		 - -% 0.19 - - 7.45 7.30 10.84 -5.2171
IDHC
Integrated Diagnostics Holdings PLC		 0.02 3.77% 0.55 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 0.45 5.36% 8.85 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -0.75 5.88% 12.00 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 -0.125 6.49% 1.80 - - 7.05 1.50 6.07 -1.6211

Reports Covered

Stock Research & News

View All

Profile

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Oxford Biodynamics PLC

3140 Rowan Place, Oxford, United Kingdom, OX4 2WB

Key Executives

Name Title Year Born
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. CEO & Director 1963
Mr. Paul Leslie Stockdale F.C.A., M.A. CFO & Director 1975
Dr. Alexandre Akoulitchev Ma (Oxon), Ph.D. Chief Scientific Officer & Director 1962
Mr. Thomas G. Guiel B.A. Chief Operating Officer NA
Dr. Jayne Green B.Sc., Ph.D. Director of Operations NA
Dr. Ewan Hunter B.Sc., BSC, Ph.D., Ph.D., (KCL) C.D.O NA
T. Demain Company Sec. NA
Dr. Steven Tucker M.D., FACP Group Clinical Director NA
Prof. Siamon Gordon Clinical Director of Inflammation & Infection NA
Dr. Sandy Primrose Ph.D. Technical Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions